Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Badura, Susanne ^a   Tesanovic, Tamara ^a   Pfeifer, Heike ^a   Wystub, Sylvia ^a   Nijmeijer, Bart A ^b   Liebermann, Marcus ^a   Falkenburg, J H Frederik ^b   Ruthardt, Martin ^a   Ottmann, Oliver G ^a  

^a GOETHE UNIVERSITY   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LYMPHOCYTES; MORPHOLINES; MULTIPROTEIN COMPLEXES; NAPHTHYRIDINES; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84893556449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080070     Document Type: Article

References (55)

1. Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signalling--which way to target? Trends Pharmacol Sci 24: 366-376. doi:10.1016/S0165-6147(03)00163-9. PubMed: 12871670. (Pubitemid 37315529)
2. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644. doi:10.1038/nrd2926. PubMed: 19644473.
3. Kharas MG, Fruman DA (2005) ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65: 2047-2053. doi:10.1158/0008-5472.CAN-04-3888. PubMed: 15781610. (Pubitemid 40490106)
4. Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL et al. (2006) Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928. doi:10.1038/sj.leu.2404245. PubMed: 16642045. (Pubitemid 43797279)
5. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY et al. (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118: 3762-3774. doi:10.1172/JCI34616. PubMed: 18830414.
6. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R et al. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16: 6151-6161. doi:10.1093/emboj/16.20. 6151. PubMed: 9321394. (Pubitemid 27458335)
7. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY et al. (2003) Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17: 995-997. doi:10.1038/sj.leu.2402874. PubMed: 12750723. (Pubitemid 36626336)
8. Ottmann OG, Wassmann B (2005) Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program: 118-122.
9. Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91: 3995-4019. PubMed: 9596644. (Pubitemid 28261960)
10. Ottmann OG, Pfeifer H (2009) Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program: 371-381.
11. Hofmann WK, Komor M, Hoelzer D, Ottmann OG (2004) Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 45: 655-660. doi:10.1080/ 10428190310001625755. PubMed: 15160936. (Pubitemid 38256025)
12. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T et al. (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118: 1208-1215. doi:10.1182/blood-2010- 12-326405. PubMed: 21562040.
13. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA et al. (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118: 3038-3050. doi:10.1172/JCI33337. PubMed: 18704194.
14. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P et al. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782. doi:10.1038/sj.leu.2403898. PubMed: 16136169. (Pubitemid 41486155)
15. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG (2011) BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. Hematol Oncol 4: 6. doi:10.1186/1756-8722-4-6. PubMed: 21299849.
16. Xing H, Yang X, Liu T, Lin J, Chen X et al. (2012) The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line. Leuk Res 36: 509-513. doi:10.1016/j.leukres.2011.12.018. PubMed: 22285507.
17. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. doi:10.1016/j.ccr.2007.05.008. PubMed: 17613433. (Pubitemid 47001784)
18. Sparks CA, Guertin DA (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29: 3733-3744. doi:10.1038/onc.2010.139. PubMed: 20418915.
19. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484. doi:10.1016/j.cell.2006.01.016. PubMed: 16469695. (Pubitemid 43199434)
20. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318. doi:10.1038/nrm2672. PubMed: 19339977.
21. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189. doi:10.1016/S0092-8674(02)00833-4. PubMed: 12150926. (Pubitemid 34876546)
22. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. doi:10.1126/science.1106148. PubMed: 15718470. (Pubitemid 40262113)
23. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLOS Biol 7: e38. doi:10.1371/journal.pbio.1000038. PubMed: 19209957.
24. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032. doi:10.1074/jbc.M900301200. PubMed: 19150980.
25. Janes MR, Limon JJ, So L, Chen J, Lim RJ et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213. doi:10.1038/nm.2091. PubMed: 20072130.
26. Brown VI, Fang J, Alcorn K, Barr R, Kim JM et al. (2003) Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 100: 15113-15118. doi:10.1073/pnas.2436348100. PubMed: 14657335. (Pubitemid 37518025)
27. Abraham RT, Eng CH (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 12: 209-222. doi:10.1517/14728222. 12.2.209. PubMed: 18208369. (Pubitemid 351284963)
28. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P et al. (2008) Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111: 379-382. doi: 10.1182/blood-2007-03-080796. PubMed: 17878402.
29. Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C et al. (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105: 2527-2534. doi:10.1182/blood-2004-06-2494. PubMed: 15550488. (Pubitemid 40387055)
30. Efeyan A, Sabatini DM (2010) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22: 169-176. doi:10.1016/j.ceb.2009.10.007. PubMed: 19945836.
31. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L et al. (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8: 742-753. doi:10.1158/1535-7163.MCT-08-0668. PubMed: 19372546.
32. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287. doi:10.1200/JCO.2008.20. 0766. PubMed: 19332717.
33. Lane HA, Breuleux M (2009) Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 21: 219-229. doi:10.1016/j.ceb.2009.01.016. PubMed: 19233631.
34. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF et al. (2011) Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res 17: 7116-7126. doi:10.1158/1078-0432.CCR-11-0796. PubMed: 21976531.
35. Maira SM, Pecchi S, Huang A, Burger M, Knapp M et al. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11: 317-328. doi:10.1158/1535-7163.MCT- 11-0474. PubMed: 22188813.
36. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863. doi:10.1158/1535-7163.MCT-08-0017. PubMed:18606717.
37. Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B et al. (2011) Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov 6: 323-338. doi:10.1517/17460441.2011.558079. PubMed: 22647206.
38. Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der Burg M et al. (2009) Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol 37: 376-385. doi:10.1016/j.exphem.2008.11.002. PubMed: 19135770.
39. Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG et al. (2008) Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet 185: 37-42. doi:10.1016/j.cancergencyto.2008.05.001. PubMed: 18656692.
40. Ren SY, Bolton E, Mohi MG, Morrione A, Neel BG et al. (2005) Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol Cell Biol 25: 8001-8008. doi:10.1128/MCB.25.18.8001-8008.2005. PubMed: 16135792. (Pubitemid 41262994)
41. Bruhn MA, Pearson RB, Hannan RD, Sheppard KE (2010) Second AKT: the rise of SGK in cancer signalling. Growth Factors 28: 394-408. doi:10.3109/08977194. 2010.518616. PubMed: 20919962.
42. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V et al. (2010) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424-5435. doi:10.1158/1078-0432.CCR-10-1102. PubMed: 20884625.
43. Ahmad EI, Gawish HH, Al Azizi NM, Elhefni AM (2011) The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine. Onco Targets Ther 4: 115-121. PubMed: 21792317.
44. Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3: 1221-1224. doi:10.4161/cc.3.10.1164. PubMed: 15467468. (Pubitemid 40268595)
45. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K et al. (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in Tcell leukemia. Nat Med 13: 1203-1210. doi:10.1038/nm1636. PubMed: 17873882. (Pubitemid 47530629)
46. Mahmoud IS, Sughayer MA, Mohammad HA, Awidi AS, El K et al. (2008) The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 99: 488-490. doi:10.1038/sj.bjc.6604512. PubMed: 18665177.
47. Müller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS et al. (2007) Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 31: 27-32. doi:10.1016/S0145-2126(07)70280-1. PubMed: 16764926. (Pubitemid 44709746)
48. Hummerdal P, Andersson P, Willander K, Linderholm M, Söderkvist P et al. (2006) Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 77: 86-87. doi:10.1111/j.0902-4441.2006.t01-1-EJH2605. x. PubMed: 16573740. (Pubitemid 43876212)
49. He Y, Zheng J, Hu Y, Xiao H, Liu J et al. (2010) Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Eur J Haematol 84: 87-88. doi:10.1111/j.1600-0609.2009. 01350.x. PubMed: 19744127.
50. Montiel-Duarte C, Cordeu L, Agirre X, Román-Gómez J, Jiménez- Velasco A et al. (2008) Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Res 32: 709-716. doi:10.1016/j.leukres.2007.09.005. PubMed: 17942153. (Pubitemid 351330173)
51. De P, Miskimins K, Dey N, Leyland-Jones B (2013) Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. Cancer Treat Rev 39: 403-412. doi:10.1016/j.ctrv.2012.12.002. PubMed: 23352077.
52. Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A et al. (2011) S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLOS ONE 6: e27509. doi:10.1371/journal.pone.0027509. PubMed: 22110663.
53. Kharas MG, Deane JA, Wong S, O'Bosky KR, Rosenberg N et al. (2004) Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103: 4268-4275. doi:10.1182/blood-2003- 07-2193. PubMed: 14976048. (Pubitemid 38685373)
54. Levy DS, Kahana JA, Kumar R (2009) AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 113: 1723-1729. doi:10.1182/blood-2008-02-137737. PubMed: 19064730.
55. Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR et al. (2013) Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 121: 2964-2974. doi:10.1182/blood-2012-08-446096. PubMed: 23403624.